News from WCM

Researchers at Weill Cornell Medicine have uncovered how a key Parkinson's protein called LRRK2 shifts between inactive and active forms, revealing the structural changes that enable certain mutations to push the protein into an overactive state. 

Artificial intelligence may enhance implementation of a new federal rule requiring aduts enrolled under the Affordable Care Act expansion of Medicaid eligibility to complete qualifying work hours or community engagement activities or meet exemption criteria to maintain coverage, according to a new commentary.

Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a phase 3 clinical trial led by Weill Cornell Medicine, NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center and investigators at several other institutions worldwide.

During development, regional dips in oxygen levels serve as a signal that triggers the coordinated growth of heart muscle and coronary vessels, according to a new study. 

A protein that can dial down oxidative stress in cells helps some cancers resist treatment with a widely used class of drugs called BTK inhibitors, according to a study led by investigators at Weill Cornell Medicine. 

A protein secreted by common cancer types makes blood vessels leakier to allow metastatic tumors to form in the lungs, according to a study led by investigators at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center.

An overactive immune response in the brain may play a role in Dravet Syndrome, a rare and severe genetic epilepsy that typically begins in infancy, according to Weill Cornell Medicine researchers. 

Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms.

Dr. Imperato-McGinley, esteemed endocrinologist, looks back at her 50-year career as a pioneer in her field and leader of the translational research enterprise at Weill Cornell Medicine. 

Weill Cornell Medicine has received a $2.5 million, three-year grant from the Department of Defense (DoD) to develop therapies with fewer side effects for triple-negative breast cancer, one of the most aggressive and difficult-to-treat breast cancers. 

Significant advances have been made in the development of patient-derived tumor organoids for preclinical research, in two new studies led by Weill Cornell Medicine investigators. 

An NSAID-related compound called ampyrone appears to safely boost production of the pigment melanin in human skin, according to a preclinical study led by Weill Cornell Medicine and National Eye Institute investigators. 

A form of glioma, a type of brain cancer, tends to progress towards greater malignancy due to an increasing tendency of the glioma cells to transform into immature, stem-cell-like states, according to a study led by investigators at Weill Cornell Medicine, the New York Genome Center, Harvard Medical School and Mass General Brigham.

Researchers at Weill Cornell Medicine and Birkbeck, University of London, have identified where a commonly used anesthetic binds to sodium ion channels, revealing a molecular mechanism that may explain how these drugs dampen communication between neurons. 

The National Institute on Aging of the National Institutes of Health has awarded a five-year grant initially worth $8.37 million for Weill Cornell Medicine researchers to study a new gene therapy for Alzheimer’s disease in people who have a high genetic risk of developing the condition. The research could garner nearly $14 million in total if prescribed milestones are reached for years three through five.

A protein produced by gut immune cells orchestrates both immune protection against pathogens and immune tolerance of gut bacteria, according to a study led by Weill Cornell Medicine investigators.

An artificial intelligence system that operates like a collaborative team of medical experts could accelerate clinical trial design, one of the most difficult steps in drug development, according to a new study by Weill Cornell Medicine investigators. 

An aging Baby Boomer generation and contracting nursing home supply will put unprecedented pressure on long-term nursing home services in the United States. 

A small subset of T cells, called stem T cells, are responsible for making new T cells and for continuously replenishing them in chronic disease, according to a team of scientists from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center.

Researchers at Columbia University Irving Medical Center and Weill Cornell Medicine have won a $17.25 million grant from the Aligning Research to Understand Autism initiative to study profound autism, which affects over one quarter of individuals who are on the autism spectrum.